Comparative proteomics analysis of human osteosarcomas and benign tumor of bone

Y, Li; Liang, Qiong; Yq, Wen; Chen, LL; Lt, Wang; Yl, Liu; Cq, Luo; Hz, Liang; Mt, Li; Z, Li

doi:10.1016/j.cancergencyto.2010.01.003

Cited by 55 publications

(56 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25, an activation time of 10 ms, and an isolation width of 2.0. Targeted ions with m/z Ϯ 10 ppm were selected for MS/MS and dynamically excluded for 60 s.…”

Section: Methodsmentioning

confidence: 99%

Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*

Yeh¹,

Hsu

Shao

et al. 2015

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Sorafenib has become the standard therapy for patients with advanced hepatocellular carcinoma (HCC). Unfortunately, most patients eventually develop acquired resistance. Therefore, it is important to identify potential biomarkers that could predict the efficacy of sorafenib. To identify target proteins associated with the development of sorafenib resistance, we applied stable isotope labelling with amino acids in cell culture (SILAC)-based quantitative proteomic approach to analyze differences in protein expression levels between parental HuH-7 and sorafenib-acquired resistance HuH-7 (HuH-7 R ) cells in vitro, combined with an isobaric tags for relative and absolute quantitation (iTRAQ) quantitative analysis of HuH-7 and HuH-7 R tumors in vivo. In total, 2,450 quantified proteins were identified in common in SILAC and iTRAQ experiments, with 81 showing increased expression (>2.0-fold) with sorafenib resistance and 75 showing decreased expression (<0.5-fold). In silico analyses of these differentially expressed proteins predicted that 10 proteins were related to cancer with involvements in cell adhesion, migration, and invasion. Knockdown of one of these candidate proteins, galectin-1, decreased cell proliferation and metastasis in HuH-7 R cells and restored sensitivity to sorafenib. We verified galectin-1 as a predictive marker of sorafenib resistance and a downstream target of the AKT/mTOR/HIF-1␣ signaling pathway. In addition, increased galectin-1 expression in HCC patients' serum was associated with poor tumor control and low response rate. We also found that a high serum galectin-1 level was an independent factor associated with poor progression-free survival and overall survival. In conclusion, these results suggest that galectin-1 is a possible biomarker for predicting the response of HCC patients to treatment with sorafenib. As such, it may assist in the stratification of HCC and help direct personalized therapy. Molecular & Cellular

show abstract

“…25, an activation time of 10 ms, and an isolation width of 2.0. Targeted ions with m/z Ϯ 10 ppm were selected for MS/MS and dynamically excluded for 60 s.…”

Section: Methodsmentioning

confidence: 99%

Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*

Yeh¹,

Hsu

Shao

et al. 2015

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

show abstract

“…There exist a number of publications describing the correlation between the expression of ZNF280B and the growth of various types of cancer (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). For example, Gunn et al (22) reported that ZNF280B acts as a tumor suppressor in chronic lymphocytic leukemia.…”

Section: Discussionmentioning

confidence: 99%

“…By interacting with DNA and proteins, ZNF proteins can provide links between these molecule types (4). An increasing number of studies has reported that ZNF proteins serve critical roles in human cancers (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15). For example, ZNF703 acts as an oncogene in invasive gastric carcinoma, and its expression levels are correlated with gastric carcinoma progression (16).…”

Section: Introductionmentioning

confidence: 99%

ZNF280B promotes the growth of gastric cancer inï¿½vitro and inï¿½vivo

et al. 2018

View full text Add to dashboard Cite

Abstract. Zinc finger protein 280B (ZNF280B) mediates pro-survival and pro-growth functions in prostate cancer. However, in gastric cancer, its clinical significance remains poorly characterized. In the present study, the expression levels of ZNF280B in 60 patients with gastric cancer were examined using immunohistochemistry. The association between ZNF280B expression and clinicopathological features was assessed. Positive ZNF280B staining was demonstrated for 38 (63.3%) samples out of 60 gastric cancer cases in immunohistochemical analysis. ZNF280B expression was significantly associated with tumor size (P= 0.017) and TNM stage (P= 0.001). Furthermore, the proliferation index in the positive ZNF280B expression group was significantly higher (38.8±6.2) compared with that of the negative ZNF280B expression group (16.9±8.9; P<0.01). These results suggest that ZNF280B expression may be associated with the proliferation of gastric cancer cells. The role of ZNF280B in the growth of gastric cancer cells (MGC-803) was also investigated in vitro and in vivo by enhancing the expression of ZNF280B. A colony formation assay indicated that the number of colonies in the MGC-803 cells with enhanced ZNF280B (146±5.8) was significantly higher than that of the MGC-803 control group (97±5.1) and the negative control group (101±6.5; P<0.05). An MTT assay demonstrated that ZNF280B significantly promoted the proliferation of MGC-803 cells at days 3 and 4 (P<0.05). It was observed that the overexpression of ZNF280B may promote the growth of gastric cancer in vivo in xenograft studies. These findings indicate that ZNF280B may be a novel therapeutic target for gastric cancer.

show abstract

“…TUBA1C, a major cytoskeletal protein, was suggested as a key protein involved in metastasis and progression of osteosarcoma and therefore might be valuable as a prognostic indicator (70). Li et al (70) also demonstrated the up regulation of ZNF133, a transcriptional repressor, in osteosarcoma tissues, but the exact function of this protein is still unknown (70). Another potential diag nostic biomarker discovered by Hua et al (67) is NDRG1, a protein that was found to be significantly upregulated in human osteosarcoma cell line and tissues.…”

Section: Biomarker For Bone Tumors From Genomics and Proteomics Studiesmentioning

confidence: 99%

“…Other potential biomarkers for osteo sarcoma uncovered by proteomics studies include cytochrome C1 (CYC1), zinc finger protein 133 (ZNF133), tubulinα1c (TUBA1C), protein NDRG1 and gelsolin (67,68,70,72). CYC1 is a hemecontaining subunit of the cytochrome bc1 complex and is mainly known as an important participant in mitochondrial adenosine 5′triphosphate (ATP) synthesis (72,75).…”

Section: Biomarker For Bone Tumors From Genomics and Proteomics Studiesmentioning

confidence: 99%

Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges

Wan-Ibrahim

Singh

Hashim

et al. 2015

Mol Med

View full text Add to dashboard Cite

Diagnosis of bone tumor currently relies on imaging and biopsy, and hence, the need to find less invasive ways for its accurate detection. More recently, numerous promising deoxyribonucleic acid (DNA) and protein biomarkers with significant prognostic, diagnostic and/or predictive abilities for various types of bone tumors have been identified from genomics and proteomics studies. This article reviewed the putative biomarkers for the more common types of bone tumors (that is, osteosarcoma, Ewing sarcoma, chondrosarcoma [malignant] and giant cell tumor [benign]) that were unveiled from the studies. The benefits and drawbacks of these biomarkers, as well as the technology platforms involved in the research, were also discussed. Challenges faced in the biomarker discovery studies and the problems in their translation from the bench to the clinical settings were also addressed.

show abstract

Comparative proteomics analysis of human osteosarcomas and benign tumor of bone

Cited by 55 publications

References 43 publications

Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*

Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*

ZNF280B promotes the growth of gastric cancer inï¿½vitro and inï¿½vivo

Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges

Contact Info

Product

Resources

About